Arcturus Therapeutics Holdings Inc.
ARCTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeArcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. At a $279.7M market cap, Arcturus Therapeutics Holdings Inc. ranks as a micro-cap company within healthcare. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Market Cap
$279.7M
Beta
2.48
P/E (TTM)
—
P/E (Fwd)
-2.66
EPS (TTM)
$-3.33
EPS (Fwd)
$-3.70
ROE
-46.3%
ROA
-24.0%
Cash
$191.5M
Total Debt
$22.9M
Free CF
$19.3M
52W Change
-7.1%
Annual Financials
Cash vs Debt
Where ARCT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, ARCT finished 11.54% above its 150-day moving average ($9.27) and 17.50% above its 200-day moving average ($8.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARCT overbought or oversold?
At the October 19, 2026 close, ARCT's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Arcturus Therapeutics Holdings Inc. holds $191.5M in cash against $22.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $19.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -46.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $205.8M (2022) to $67.2M (2025), a 67% decline worth watching.
A beta of 2.48 means ARCT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Arcturus Therapeutics Holdings Inc. and its sector.